Santé Ventures Research
Investment Thesis
Santé Ventures is a specialized healthcare and life sciences investment firm founded in 2006 and based in Austin, Texas, with a second office in Boston. The firm invests at the forefront of healthcare and technology innovation, combining deep healthcare industry experience (cellular biology, medicine, therapeutic development, physician and hospital leadership, public policy) with scientific and technology expertise. Santé's stated firm pillars are generating returns, improving lives, unleashing talent, advancing technology, and pursuing excellence. Alongside its venture arm, Santé Capital runs a separate publicly-traded securities strategy powered by a proprietary machine-learning system called MindRank, though that strategy sits outside the venture/private-company mandate this profile covers.
Sector Focus
Santé Ventures concentrates on three healthcare sub-sectors: Biotech, Medtech, and Healthtech. Its portfolio spans clinical-stage therapeutics (oncology, Wnt-pathway inhibitors, CNS), interventional medical devices (cardiac ablation, stroke aspiration, endovascular tools, mitral valve repair, airway scaffolds), and digitally enabled or AI-driven healthcare services (ambient AI in surgery, breast-cancer risk AI, at-home cancer care, revenue-cycle and reimbursement software).
Stage Focus
Santé describes itself as an early-stage investor that "leads entry rounds" for the healthcare and life science companies it backs, though its five funds have also participated in later growth rounds (e.g., Series B financings) as portfolio companies mature. Public fund materials reference typical target ownership of 20%+ per portfolio company at entry.
Check Size
Third-party fund trackers place Santé's average initial check in the $1M-$3M range, consistent with a lead-investor posture at seed through Series A, with meaningful reserves for follow-on participation in later rounds.
Lead Tendency
Santé explicitly states it "leads entry rounds for innovative healthcare and life science companies that are well-positioned to improve patient outcomes," indicating a strong lead-investor posture at first check.
Recent Activity
Santé closed its fifth fund, Santé Health Ventures V, at $330M in February 2026 (exceeding its $300M target), bringing total assets under management to over $1 billion. The firm has been actively deploying and supporting portfolio companies through 2026, including ReEmerge's oversubscribed $37M Series A (September 2026), RapidPulse's oversubscribed $48M Series B for stroke-aspiration technology (July 2026), and an $80M funding round for Endovascular Engineering (June 2026). Portfolio company Kestrel Therapeutics received FDA Fast Track Designation for its KRAS inhibitor KST-6051 in September 2026, and Iterion Therapeutics presented clinical validation data for Tegavivint at the 2026 ASCO Annual Meeting.
Portfolio Highlights
Santé's roughly 30-company active portfolio includes clinical-stage biotechs (Kestrel Therapeutics, Iterion Therapeutics, Sensorium Therapeutics, MycRx, Geneos Therapeutics), medtech/device companies (Farapulse, acquired by Boston Scientific; Millipede; Endogenex; Endovascular Engineering; Sonire Therapeutics; RapidPulse), and healthtech/AI companies (BeeKeeperAI, Clairity, Aimbient — formerly Surgical Safety Technologies, Reimagine Care, RevelloHealth, Healthcare Highways, CareHive). Fund history spans Fund I (2007) through Fund V (2024/2026 close), reflecting nearly two decades of continuous deployment.
Team
- Kevin Lalande, Founding Managing Director & Chief Investment Officer
- Joe Cunningham, MD, Founding Managing Director
- Douglas French, Founding Managing Director
- James Eadie, MD, Managing Director
- Omar Khalil, Managing Director
- Dennis McWilliams, Managing Director
- Casey Cunningham, MD, Partner & Chief Scientific Officer
- Ashley Seehusen, Louis Bock, Thomas Krummel MD, and William Cohn MD, Venture Partners
- Jeff Crawford, Head of Finance; Brooke Jones, Head of Capital Formation; Diane Brouillard, Head of Talent & Networks
- A bench of Principals, Senior Associates, Venture Fellows, and operating/finance staff rounding out a team of roughly 30
The partnership has been investing together for more than twenty years per the firm's own team-page framing, indicating high continuity among the founding Managing Directors.
Decision Process
Santé operates as a multi-partner investment team (three Founding Managing Directors plus additional Managing Directors and a Chief Scientific Officer), consistent with a partnership-style decision process rather than a solo-GP structure.
Founder Preferences
Santé's public materials emphasize partnering with "talented entrepreneurs" and "visionary entrepreneurs" building disruptive technologies in Biotech, Medtech, and Healthtech, with particular emphasis on technical/scientific founding teams (physicians, scientists, engineers) given the firm's own bench of MD and PhD-level partners.
Geographic Focus
Santé invests nationally from its Austin, Texas headquarters and Boston, Massachusetts office, with historical roots emphasizing the Central US market at founding in 2006-2007.